Would you treat a postmenopausal women with high grade T2N0 ER-, PR+, HER2- invasive ductal carcinoma with upfront surgery or neoadjuvant chemotherapy?

I'd conduct a conversation about NAC, but it isn't clear to me that NAC would change anything for this patient. PR 45% does not qualify as "functionally triple negative" in my book, so I'd consider this still HR+. I would not offer more than AC-T whether NAC or adjuvant. Additionally, I wouldn't off...